[HTML][HTML] Possible long-term efficacy of sitagliptin, a dipeptidyl peptidase-4 inhibitor, for slowly progressive type 1 diabetes (SPIDDM) in the stage of non-insulin …
…, S Kurihara, Y Miyashita, M Hatano, Y Ikegami… - Diabetes Therapy, 2017 - Springer
Introduction We tested the hypothesis that dipeptidyl peptidase-4 (DPP-4) inhibitors are effective
in preserving the β-cell function for long-term periods in patients with slowly progressive …
in preserving the β-cell function for long-term periods in patients with slowly progressive …
[HTML][HTML] The annual rate of coronary artery calcification with combination therapy with a PCSK9 inhibitor and a statin is lower than that with statin monotherapy
Y Ikegami, I Inoue, K Inoue, Y Shinoda, S Iida… - NPJ aging and …, 2018 - nature.com
Statins and/or PCSK9 inhibitors cause the regression of coronary atheroma and reduce
clinical events. However, it currently remains unclear whether these drugs modulate coronary …
clinical events. However, it currently remains unclear whether these drugs modulate coronary …
LKB1, an upstream AMPK kinase, regulates glucose and lipid metabolism in cultured liver and muscle cells
K Imai, K Inukai, Y Ikegami, T Awata… - … and biophysical research …, 2006 - Elsevier
LKB1 is a 50kDa serine/threonine kinase that phosphorylates and activates the catalytic
subunit of AMPK at its T-loop residue Thr 172. We prepared adenoviruses expressing the …
subunit of AMPK at its T-loop residue Thr 172. We prepared adenoviruses expressing the …
[HTML][HTML] Burn-induced muscle metabolic derangements and mitochondrial dysfunction are associated with activation of HIF-1α and mTORC1: Role of protein …
…, K Ikeda, S Shinozaki, M Kobayashi, Y Ikegami… - Scientific reports, 2017 - nature.com
Metabolic derangements are a clinically significant complication of major trauma (eg, burn
injury) and include various aspects of metabolism, such as insulin resistance, muscle wasting, …
injury) and include various aspects of metabolism, such as insulin resistance, muscle wasting, …
Effects of dapagliflozin on renin-angiotensin-aldosterone system under renin-angiotensin system inhibitor administration
…, H Kitazato, D Ito, D Saito, M Hatano, Y Ikegami… - Endocrine …, 2020 - jstage.jst.go.jp
Sodium–glucose cotransporter-2 inhibitors (SGLT2Is) are reported to prevent cardiovascular
events by a mechanism possibly including diuresis and sodium excretion. In this respect, …
events by a mechanism possibly including diuresis and sodium excretion. In this respect, …
Low‐dose farnesyltransferase inhibitor suppresses HIF‐1α and snail expression in triple‐negative breast cancer MDA‐MB‐231 cells in vitro
T Tanaka, Y Ikegami, H Nakazawa… - Journal of Cellular …, 2017 - Wiley Online Library
The aggressiveness of triple‐negative breast cancer (TNBC), which lacks estrogen receptor,
progesterone receptor and epidermal growth factor receptor 2 (HER2), represents a major …
progesterone receptor and epidermal growth factor receptor 2 (HER2), represents a major …
Detailed time course of decline in serum C-peptide levels in anti–programmed cell death-1 therapy–induced fulminant type 1 diabetes
D Saito, Y Oikawa, Y Yano, Y Ikegami… - Diabetes …, 2019 - Am Diabetes Assoc
Fulminant type 1 diabetes (FT1D) is a novel subtype of type 1 diabetes (T1D) and is
characterized by a relatively low glycated hemoglobin (HbA1c) level at onset, despite the abrupt …
characterized by a relatively low glycated hemoglobin (HbA1c) level at onset, despite the abrupt …
Adiponectin upregulates ferritin heavy chain in skeletal muscle cells
Y Ikegami, K Inukai, K Imai, Y Sakamoto, H Katagiri… - Diabetes, 2009 - Am Diabetes Assoc
OBJECTIVE—Adiponectin is an adipocyte-derived protein that acts to reduce insulin resistance
in the liver and muscle and also inhibits atherosclerosis. Although adiponectin reportedly …
in the liver and muscle and also inhibits atherosclerosis. Although adiponectin reportedly …
Involvement of low adiponectin levels in impaired glucose tolerance
Y Nakashima, K Inukai, K Imai, Y Ikegami, T Awata… - Metabolism, 2008 - Elsevier
To investigate the association between serum adiponectin levels and 2-hour post–75-g oral
glucose load glycemia, we conducted 75-g oral glucose tolerance tests in 50 subjects who …
glucose load glycemia, we conducted 75-g oral glucose tolerance tests in 50 subjects who …
[HTML][HTML] Anagliptin Monotherapy for Six Months in Patients with Type 2 Diabetes Mellitus and Hyper-Low-Density Lipoprotein Cholesterolemia Reduces Plasma …
Y Ikegami, Y Takenaka, D Saito… - Journal of Clinical …, 2021 - ncbi.nlm.nih.gov
Background Anagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, has been shown to
decrease plasma low-density lipoprotein cholesterol (LDL-C) levels. The objective of our study …
decrease plasma low-density lipoprotein cholesterol (LDL-C) levels. The objective of our study …
